AveXis, Inc. (AVXS) Shares Bought by Rhumbline Advisers

Rhumbline Advisers raised its stake in shares of AveXis, Inc. (NASDAQ:AVXS) by 22.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,885 shares of the company’s stock after buying an additional 5,203 shares during the quarter. Rhumbline Advisers owned about 0.09% of AveXis worth $2,697,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Morgan Stanley grew its holdings in shares of AveXis by 8.4% in the first quarter. Morgan Stanley now owns 22,681 shares of the company’s stock worth $1,724,000 after acquiring an additional 1,758 shares during the period. Schwab Charles Investment Management Inc. lifted its position in AveXis by 7.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 54,865 shares of the company’s stock valued at $4,172,000 after purchasing an additional 3,579 shares in the last quarter. Russell Investments Group Ltd. lifted its position in AveXis by 41.7% during the second quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock valued at $2,043,000 after purchasing an additional 7,321 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in AveXis by 2.9% during the second quarter. Pictet Asset Management Ltd. now owns 158,062 shares of the company’s stock valued at $11,183,000 after purchasing an additional 4,456 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in AveXis during the second quarter valued at $509,000. Institutional investors and hedge funds own 92.88% of the company’s stock.

In related news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $94.77, for a total value of $168,690.60. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $168,690.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,340 shares of company stock worth $5,172,298. Insiders own 18.60% of the company’s stock.

Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Chardan Capital restated a “buy” rating on shares of AveXis in a research report on Thursday, November 2nd. Royal Bank Of Canada restated a “hold” rating and issued a $92.00 price objective on shares of AveXis in a research report on Thursday, November 2nd. Jefferies Group boosted their price objective on AveXis to $118.00 and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $130.00 price objective (up from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the stock. AveXis currently has an average rating of “Buy” and a consensus price target of $110.67.

AveXis, Inc. (AVXS) opened at $99.83 on Friday. AveXis, Inc. has a 52 week low of $44.68 and a 52 week high of $108.27.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the previous year, the company earned ($0.87) earnings per share. equities analysts expect that AveXis, Inc. will post -6.23 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “AveXis, Inc. (AVXS) Shares Bought by Rhumbline Advisers” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://weekherald.com/2017/12/10/avexis-inc-avxs-shares-bought-by-rhumbline-advisers.html.

AveXis Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply